New malaria vaccine shows promise in early human trial
NCT ID NCT06735209
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 8 times
Summary
This early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than earlier vaccines. Researchers will check if it is safe, well-tolerated, and whether it can prevent infection when volunteers are later exposed to malaria under controlled conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PfSPZ-LARC2 vaccine (genetically weakened malaria parasites)
- What this could lead to
- If successful, this could lead to a more effective malaria vaccine that provides stronger and longer-lasting protection than current options.
- What could go wrong
- This is a very early Phase 1 trial with only 22 people, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Washington - Virology Research Clinic
Seattle, Washington, 98104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth